Merck & Co. (MRK) : Graybill Bartz Assoc Ltd added new position in Merck & Co. during the most recent quarter end. The investment management firm now holds 60,355 shares of Merck & Co. which is valued at $3.3 Million according to a report filed by the company on Apr 5, 2016 with the SEC.Merck & Co. makes up approximately 3.04% of Graybill Bartz Assoc Ltd’s portfolio.
Other Hedge Funds, Including , West Oak Capital boosted its stake in MRK in the latest quarter, The investment management firm added 600 additional shares and now holds a total of 8,950 shares of Merck & Co. which is valued at $492,698. Merck & Co. makes up approx 0.38% of West Oak Capital’s portfolio.Lvm Capital Management Ltdmi reduced its stake in MRK by selling 200 shares or 1.78% in the most recent quarter. The Hedge Fund company now holds 11,018 shares of MRK which is valued at $606,541. Merck & Co. makes up approx 0.19% of Lvm Capital Management Ltdmi’s portfolio.Renaissance Investment Group boosted its stake in MRK in the latest quarter, The investment management firm added 94 additional shares and now holds a total of 85,927 shares of Merck & Co. which is valued at $4.6 Million. Merck & Co. makes up approx 2.31% of Renaissance Investment Group’s portfolio.Beacon Financial Group boosted its stake in MRK in the latest quarter, The investment management firm added 1,120 additional shares and now holds a total of 9,251 shares of Merck & Co. which is valued at $496,779. Merck & Co. makes up approx 0.11% of Beacon Financial Group’s portfolio.Cacti Asset Management reduced its stake in MRK by selling 17,275 shares or 2.76% in the most recent quarter. The Hedge Fund company now holds 608,219 shares of MRK which is valued at $32.7 Million. Merck & Co. makes up approx 3.51% of Cacti Asset Management’s portfolio.
On the company’s financial health, Merck & Co. reported $0.93 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Feb 3, 2016. Analyst had a consensus of $0.91. The company had revenue of $10215.00 million for the quarter, compared to analysts expectations of $10355.20 million. The company’s revenue was down -2.5 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.87 EPS.
Many Wall Street Analysts have commented on Merck & Co.. Societe Generale Initiated Merck & Co. on Apr 6, 2016 to “Buy”, Price Target of the shares are set at $80.Merck & Co. was Downgraded by BofA/Merrill to ” Neutral” on Jan 27, 2016.
Merck & Co. closed down -0.31 points or -0.56% at $55.05 with 70,65,601 shares getting traded on Monday. Post opening the session at $55.37, the shares hit an intraday low of $54.98 and an intraday high of $55.74 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Companys animal health products are sold to veterinarians distributors and animal producers.